OTCMKTS:ARGSQ - Argos Therapeutics Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.05
+0.30 (1.20%)
1 month | 3 months | 12 months
Get New Argos Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ARGSQ and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ARGSQ

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Argos Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.05.
N/A
The current consensus among 0 investment analysts is to n/a stock in Argos Therapeutics. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/10/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/9/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/8/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/6/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/4/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/3/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/1/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/3/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetDetails
4/19/2017(FBRC)Lower Price TargetMkt Perform ➝ Mkt Perform$40.00 ➝ $24.00
i
Rating by E. White at (FBRC)
3/17/2017Stifel NicolausLower Price TargetHold$24.00
i
2/23/2017(FBRC)Reiterated RatingHold
i
Rating by E. White at (FBRC)
2/22/2017Needham & Company LLCDowngradeBuy ➝ Hold
i
2/22/2017JMP SecuritiesDowngradeOutperform ➝ Market Perform
i
2/22/2017(FBRC)DowngradeOutperform ➝ Market Perform$260.00 ➝ $40.00
i
Rating by Edward White at (FBRC)
2/22/2017Stifel NicolausDowngradeBuy ➝ Hold$28.00
i
1/17/2017(FBRC)Reiterated RatingBuy$260.00
i
Rating by edward white at (FBRC)
12/9/2016Needham & Company LLCReiterated RatingBuy$200.00
i
Rating by Chad Messer at Needham & Company LLC
8/11/2016(FBRC)Lower Price TargetOutperform$280.00 ➝ $260.00
i
Rating by Edward White at (FBRC)
6/20/2016Piper Jaffray CompaniesReiterated RatingOverweight$220.00
i
Rating by Charles Duncan at Piper Jaffray Companies
6/17/2016Needham & Company LLCReiterated RatingBuy$220.00
i
Rating by Chad Messer at Needham & Company LLC
6/14/2016(FBRC)Reiterated RatingBuy
i
Rating by Edward White at (FBRC)
5/14/2016(FBRC)Reiterated RatingBuy
i
Rating by Edward White at (FBRC)
4/23/2016Needham & Company LLCReiterated RatingBuy
i
Rating by Chad Messer at Needham & Company LLC
4/19/2016Roth CapitalBoost Price TargetBuy$220.00 ➝ $360.00
i
3/30/2016Stifel NicolausLower Price TargetBuy$320.00 ➝ $200.00
i
3/19/2016(FBRC)Reiterated RatingBuy
i
Rating by Edward White at (FBRC)
3/17/2016(FBRC)Lower Price TargetOutperform$320.00 ➝ $280.00
i
Rating by Edward White at (FBRC)
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$340.00 ➝ $240.00
i
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$340.00 ➝ $240.00
i
3/9/2016(FBRC)Reiterated RatingOutperform
i
Rating by Edward White at (FBRC)
3/8/2016Needham & Company LLCLower Price TargetBuy$280.00 ➝ $220.00
i
Rating by Chad Messer at Needham & Company LLC
3/7/2016Piper Jaffray CompaniesReiterated RatingBuy$220.00
i
Rating by Benji Star at Piper Jaffray Companies
(Data available from 3/3/2016 forward)
Argos Therapeutics logo
Argos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company develops immunotherapies based on its proprietary technology platform, Arcelis. Its product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma. The company also develops AGS-004, which is in Phase II clinical trials for the treatment of human immunodeficiency virus. The company was formerly known as Merix Bioscience, Inc. and changed its name to Argos Therapeutics, Inc. in October 2004. Argos Therapeutics, Inc. was founded in 1997 and is based in Durham, North Carolina. On November 30, 2018, Argos Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the District of Delaware.
Read More

Today's Range

Now: $0.05
$0.05
$0.05

50 Day Range

MA: $0.05
$0.05
$0.05

52 Week Range

Now: $0.05
$0.02
$0.25

Volume

N/A

Average Volume

13,394 shs

Market Capitalization

$571,698.00

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.47

Frequently Asked Questions

What sell-side analysts currently cover shares of Argos Therapeutics?

The following Wall Street sell-side analysts have issued research reports on Argos Therapeutics in the last year:
View the latest analyst ratings for ARGSQ.

What is the current price target for Argos Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Argos Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Argos Therapeutics in the next year.
View the latest price targets for ARGSQ.

What is the current consensus analyst rating for Argos Therapeutics?

Argos Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ARGSQ.

What other companies compete with Argos Therapeutics?

How do I contact Argos Therapeutics' investor relations team?

Argos Therapeutics' physical mailing address is 4233 TECHNOLOGY DR, DURHAM NC, 27704. The biopharmaceutical company's listed phone number is 919-287-6300. The official website for Argos Therapeutics is www.argostherapeutics.com.